Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.06 -0.65%

-$0.02 today

Market cap
$106.78M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.02M

Average 0.04M

CLLS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Cellectis S.A.NASDAQ: CLLS

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to $0

Q1 FY2026 stock-based compensation was $0, compared with $976K a year earlier. Trailing-twelve-month stock-based compensation was $1.28M.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $320.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$1.28M-60.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Stock-Based Compensation vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -60.6% is the 7th highest of 9, against a peer median of -13.1%.
  • Stock-based compensation amounts to 1.9% of revenue for CLLS, versus a peer median of 125.0%.
CLLS Competitors
Stock-Based Compensation for CLLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SLNSilence Therapeutics plcLTM Mar 2026$14.34M USD—-14.0%1556.3%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$7.15M USD-15.9%+1.9%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$7.02M USD-5.4%+66.3%—
MREOMereo BioPharma Group plcLTM Mar 2026$6.93M USD-9.1%+16.8%1385.0%
DBVTDBV Technologies S.A.LTM Mar 2026$5.99M USD+37.2%+2.3%—
KRROKorro Bio, Inc.LTM Mar 2026$4.8M USD-10.4%+88.7%125.0%
AMRNAmarin Corporation plcLTM Mar 2026$3.95M USD-191.3%—1.8%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$2.88M USD-66.7%-9.8%—
ACIUAC Immune S.A.LTM Dec 2025CHF 2.68M CHF-42.8%—75.0%
CLLSCellectis S.A.LTM Mar 2026$1.28M USD-60.6%—1.9%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$0 USD———
Peer median (excluding CLLS) —-13.1%+2.3%125.0%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(96.75M)(98.69M)(116.84M)(36.7M)(67.8M)
Depreciation & Amortization14.16M18.44M18.52M19.84M20.12M
Deferred Income Tax087K371K00
Stock-Based Compensation11.49M6.04M5.23M00
Change in Working Capital(12.3M)(5.72M)(3.99M)53.57M(41.72M)
Accounts Receivables(12.44M)(8.99M)2.25M(6.72M)(4.44M)
Inventory215K0000
Accounts Payables177K3.25M(6.31M)2.05M(3.27M)
Other Working Capital(252K)23K67K58.24M(34.01M)
Other Non-Cash Items(21.17M)(7.6M)71.95M(14.61M)49.26M
Operating Cash Flow(104.56M)(87.44M)(24.75M)22.1M(40.14M)
Capital Expenditures(18.56M)(2.44M)(1.07M)(2.58M)(2.37M)
Acquisitions (Net)00000
Purchases of Investments(143K)00(162.48M)(160.27M)
Sales of Investments15M126K063.69M134.24M
Other Investing Activities10.97M(456K)(14.44M)00
Investing Cash Flow7.28M(2.76M)(15.51M)(102.63M)(29.58M)
Debt Repayment(10.64M)(6.6M)24.56M18.17M(5.4M)
Common Stock Issued44.64M067.94M82.68M44.14K
Common Stock Repurchased0(569K)000
Dividends Paid00000
Other Financing Activities13.53M8.32M(9.64M)(11.04M)(10.85M)
Financing Cash Flow47.53M1.15M82.87M89.8M(16.2M)
Effect of Forex Changes(5.75M)(3.36M)884K(2.73M)6.24M
Net Change in Cash(55.51M)(92.42M)43.49M6.54M(79.67M)
Free Cash Flow(123.12M)(89.89M)(25.82M)19.52M(42.5M)

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.